The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja (cefiderocol) and advance the antibiotic as a medical countermeasure against biological threats.

The contract marks one of the largest public-private investments in antimicrobial resistance preparedness in recent years.

What is the contract?

Shionogi Inc., the New Jersey-based U.S. subsidiary of Japan's Shionogi, received the award through the Biomedical Advanced Research and Development Authority’s (BARDA)'s Project BioShield program.¹

The project funds development and procurement of medical countermeasures against chemical, biological, radiological, and nuclear threats. The contract is initially funded at $119 million with multiyear options that could bring the total to $482 million.¹

The funding is expected to support four objectives:

• Establish a U.S. drug product manufacturing site for Fetroja.
• Procuring supply of the drug for government stockpiles.
• Advancing Fetroja for infections caused by high-priority biothreat pathogens including Burkholderia pseudomallei, the bacterium responsible for melioidosis, and Yersinia pestis, which causes plague.
• Pursuing an FDA supplemental application to expand Fetroja's use to pediatric patients with hospital-acquired and ventilator-associated bacterial pneumonia.

What is Fetroja?

Fetroja is the world's first siderophore cephalosporin antibiotic, a novel class that uses iron transport mechanisms to penetrate bacteria that have developed resistance to conventional antibiotics.¹

The treatment was approved back in 2020 from FDA for adults with hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated urinary tract infections caused by certain Gram-negative organisms, a category that includes some of the most treatment-resistant pathogens in clinical medicine.²

Its mechanism makes it particularly relevant as a biodefense asset. Gram-negative bacteria such as Burkholderia pseudomallei and Yersinia pestis are classified as high-priority biothreat agents by the U.S. government, and the limited arsenal of effective treatments for drug-resistant strains creates a national security vulnerability that the BARDA contract is designed to address.

How does this fit Shionogi's strategy?

Shionogi has positioned itself as one of the few large pharmaceutical companies still making sustained investments in antibiotic development, a field many companies have exited due to challenging economics.

Nathan McCutcheon, president and CEO of Shionogi Inc., said the BARDA contract complements the company's existing government collaborations and enables its U.S. expansion to proceed at greater pace and scale.

“Shionogi is proud of our ongoing commitment to combating antimicrobial resistance, as shown by the continued investment in Fetroja since its introduction in 2020, expanding our portfolio with the acquisition of Qpex Biopharma, Inc. in 2023, and further investing in Qpex to establish a new research facility dedicated to advancing antimicrobial research and development in 2025,” said McCutcheon.

The establishment of a domestic manufacturing site for Fetroja also addresses a longstanding concern in public health preparedness, the dependence on overseas production for critical antibiotics that may be needed during a national health emergency.

The award is the latest in a series of moves that have elevated Shionogi's U.S. profile. The company recently completed the $2.5 billion acquisition of global rights to Radicava for ALS and separately finalized a transaction with Apnimed involving its sleep disorder joint venture, signaling a broad push to expand its commercial and strategic footprint in the American market.

Sources

1. Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats Shionogi April 8, 2026 https://www.shionogi.com/us/en/news/2026/04/shionogi-receives-contract-with-us-government-through-bardas-project-bioshield-to-enhance-national-preparedness-for-drug-resistant-bacterial-threats.html
2. Shionogi Announces FDA Approval of FETROJA® (Cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Shionogi September 27, 2020 https://www.shionogi.com/us/en/news/2020/9/shionogi-announces-fda-approval-of-fetroja-cefiderocol-for-the-treatment-of-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia.html
3. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial National Library of Medicine October 12, 2020 https://pubmed.ncbi.nlm.nih.gov/33058798/